The EPS projection of Argos Therapeutics, Inc. (NASDAQ:ARGS) for quarter ended 2016-09-30 is $-0.4. Last week, the projection for EPS was $-0.4 against target of $-0.4, a month earlier. While 2-months ago, this projection was $-0.4 versus forecast of $-0.4a quarter months earlier, posting a deviation of 0%.
Argos Therapeutics, Inc. (NASDAQ:ARGS) posted that 18 days earlier, the share price was revised 2 times on upside. In addition, negative revisions were 0.
In last week, negative EPS revisions were 0 times and positive EPS revisions were 0 times. In last one-month and two month the positive revisions were 0 and 3. While in last 120 and 90 days, positive revisions were 3, and 3, correspondingly.
The per-share earnings downgrade for Argos Therapeutics, Inc. (NASDAQ:ARGS) in the preceding 30 and 120 were 0 and 0. While in 60 and 90 days were 0, and 0, in that order.
Argos Therapeutics, Inc. (NASDAQ:ARGS) EPS target was $-0.4 for the quarter closed 1. It was based on 3 calls. As on 2016-05-12 the EPS was $-0.57. The change was $-0.01, posting a deviation of -1.79%. The price projections gave a standard deviation of 0.13.
Quarterly Sales Estimates
Argos Therapeutics, Inc. (NASDAQ:ARGS) sales prediction for the fiscal 2016 stands at $1.49 and the median estimate is at $0.15. Almost 3 analysts gave sales target.
Among this, the highest sales estimate is $4.2 while the lowest target is $0.12 showing standard deviation of 2.346%.
As many as 3 analysts have positive sales targets revision while 3 reduced sales estimates, posting a deviation of 0%.
Last month, 3 experts have positive sales number revision. Also, 3 research groups lowered the sales projections, posting a deviation of 0%.
A quarter ago, 3 hiked sales target and 3 reduced sales forecast, posting a deviation of 1360.784%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...